Stage iiia breast cancer Trials in Nashville, United States
Conditions / Stage iiia breast cancer / Nashville, United States
Research into Stage iiia breast cancer spans multiple therapeutic approaches and trial phases.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03188393 | Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery | COMPLETED | PHASE2 |
| NCT01953588 | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01901094 | Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00066690 | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | COMPLETED | PHASE3 |
| NCT00513292 | Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery | COMPLETED | PHASE3 |
| NCT02488967 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02728596 | S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) | COMPLETED | NA |